Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous Hsp90 inhibition by geldanamycin and proteasome inhibition by velcade

Molecular Cancer Research

Volumn 4, Issue 9, 2006, Pages 667-681

  Mimnaugh, Edward G ^a   Xu, Wanping ^a   Vos, Michele ^a   Yuan, Xitong ^a   Neckers, Len ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEASOME INHIBITOR; PROTEIN P97; SMALL INTERFERING RNA; TUNICAMYCIN; YELLOW FLUORESCENT PROTEIN;

AGGRESOME; ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CELL SURFACE; CELL VACUOLE; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOPLASM; DRUG MECHANISM; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN TARGETING; UBIQUITINATION;

ANIMALS; BENZOQUINONES; BORONIC ACIDS; CELL CYCLE PROTEINS; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOPLASMIC RETICULUM; GENES, ERBB-2; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; PYRAZINES; RNA, SMALL INTERFERING; TUNICAMYCIN; UBIQUITINS; VACUOLES;

EID: 33749352630     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0019     Document Type: Article

References (99)

1. Welch WJ. Heat shock proteins functioning as molecular chaperones: their roles in normal and stressed cells. Philos Trans R Soc Lond B Biol Sci 1993;339:327-33.
2. Wegele H, Muller L, Buchner J. Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004;151:1-44.
3. v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994;91:8324-8.
4. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73.
5. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics-an update. Expert Opin Emerg Drugs 2005;10:137-49.
6. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 1997;14:2809-16.
7. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000;11:355-60.
8. Workman P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 2003;3:297-300.
9. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004;3:1021-30.
10. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
11. Miyata Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 2005;11:1131-8.
12. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50.
13. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75.
14. Grenert JP, Sullivan WP, Fadden P, et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997;272:23843-50.
15. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801.
16. Loo MA, Jensen TJ, Cui L, Hou Y, Chang XB, Riordan JR. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J 1998;17:6879-87.
17. Mimnaugh EG, Neckers LM. Measuring ubiquitin conjugation in cells. Methods Mol Biol 2005;301:223-41.
18. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-98.
19. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000;10:524-30.
20. Mimnaugh EG, Xu W, Vos M, et al. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 2004;3:551-66.
21. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Anti-myeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-100.
22. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
23. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002;6:493-500.
24. Cusack JC. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 2003;29 Suppl 1:21-31.
25. Wright JJ, Zerivitz K, Schoenfeldt M. Clinical trials referral resource. Current clinical trials of bortezomib. Oncology (Huntingt) 2003;17:677-80, 676-83, 672-91.
26. Corboy MJ, Thomas PJ, Wigley WC. Aggresome formation. Methods Mol Biol 2005;301:305-27.
27. Brewer JW, Diehl JA. PERK mediates cell-cycle exit during the mammalian unfolded protein response. Proc Natl Acad Sci U S A 2000;97:12625-30.
28. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res 2005;569:29-63.
29. Hampton RY. ER stress response: getting the UPR hand on misfolded proteins. Curr Biol 2000;10:R518-21.
30. Lawson B, Brewer JW, Hendershot LM. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway. J Cell Physiol 1998;174:170-8.
31. Bush KT, Goldberg AL, Nigam SK. Proteasome inhibition leads to a heatshock response, induction of endoplasmic reticulum chaperones and thermotolerance. J Biol Chem 1997;272:9086-92.
32. Friedlander R, Jarosch E, Urban J, Volkwein C, Sommer T. A regulatory link between ER-associated protein degradation and the unfolded-protein response. Nat Cell Biol 2000;2:379-84.
33. Romisch K. Endoplasmic reticulum-associated degradation. Annu Rev Cell Dev Biol 2005;21:435-56.
34. Hiller MM, Finger A, Schweiger M, Wolf DH. ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway. Science 1996;273:1725-8.
35. McCracken AA, Brodsky JL. Evolving questions and paradigm shifts in endoplasmic-reticulum-associated degradation (ERAD). BioEssays 2003;25:868-77.
36. Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 2004;429:841-7.
37. Bays NW, Hampton RY. Cdc48-1-Np14: stuck in the middle with Ub. Curr Biol 2002;12:R366-71.
38. Jarosch E, Geiss-Friedlander R, Meusser B, Walter J, Sommer T. Protein dislocation from the endoplasmic reticulum-pulling out the suspect. Traffic 2002;3:530-6.
39. Ye Y, Meyer HH, Rapoport TA. Function of the p97-1-Np14 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J Cell Biol 2003;162:71-84.
40. Zhong X, Shen Y, Ballar P, Apostolou A, Agami R, Fang S. AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation. J Biol Chem 2004;279:45676-84.
41. Richly H, Rape M, Braun S, Rumpf S, Hoege C, Jentsch S. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005;120:73-84.
42. Ye Y, Shibata Y, Kikkert M, van Voorden S, Wiertz E, Rapoport TA. Inaugural Article: Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. Proc Natl Acad Sci US A2005;102:14132-8.
43. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001;3:740-4.
44. Miller P, DiOrio C, Moyer M, et al. Depletion of the erbB-2 gene product p 185 by benzoquinoid ansamycins. Cancer Res 1994;54:2724-30.
45. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005;65:6401-8.
46. Xiong X, Chong E, Skach WR. Evidence that endoplasmic reticulum (ER)-associated degradation of cystic fibrosis transmembrane conductance regulator is linked to retrograde translocation from the ER membrane. J Biol Chem 1999;274:2616-24.
47. Ali A, Bharadwaj S, O'Carroll R, Ovsenek N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol Cell Biol 1998;18:4949-60.
48. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000;6:3312-8.
49. Marcu MG, Doyle M, Bertolotti A, Ron D, Hendershot L, Neckers L. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1α. Mol Cell Biol 2002;22:8506-13.
50. Kawazoe Y, Nakai A, Tanabe M, Nagata K. Proteasome inhibition leads to the activation of all members of the heat-shock-factor family. Eur J Biochem 1998;255:356-62.
51. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374-9.
52. Ma Y, Hendershot LM. The mammalian endoplasmic reticulum as a sensor for cellular stress. Cell Stress Chaperones 2002;7:222-9.
53. Rabinovich E, Kerem A, Frohlich KU, Diamant N, Bar-Nun S. AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. Mol Cell Biol 2002;22:626-34.
54. Rouiller I, DeLaBarre B, May AP, et al. Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle. Nat Struct Biol 2002;9:950-7.
55. Song C, Wang Q, Li CC. ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. J Biol Chem 2003;278:3648-55.
56. Jarosch E, Taxis C, Volkwein C, et al. Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48. Nat Cell Biol 2002;4:134-9.
57. Meyer HH, Wang Y, Warren G. Direct binding of ubiquitin conjugates by the mammalian p97 adaptor complexes, p47 and Ufd1-4. EMBO J 2002;21:5645-52.
58. Flierman D, Ye Y, Dai M, Chau V, Rapoport TA. Polyubiquitin serves as a recognition signal, rather than a ratcheting molecule, during retrotranslocation of proteins across the endoplasmic reticulum membrane. J Biol Chem 2003;278:34774-82.
59. Hirabayashi M, Inoue K, Tanaka K, et al. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ 2001;8:977-84.
60. Wojcik C. An inhibitor of the chymotrypsin-like activity of the proteasome (PSI) induces similar morphological changes in various cell lines. Folia Histochem Cytobiol 1997;35:211-4.
61. Marquardt T, Helenius A. Misfolding and aggregation of newly synthesized proteins in the endoplasmic reticulum. J Cell Biol 1992;117:505-13.
62. Casagrande R, Stern P, Diehn M, et al. Degradation of proteins from the ER of S. cerevisiae requires an intact unfolded protein response pathway. Mol Cell 2000;5:729-35.
63. Jorgensen MM, Bross P, Gregersen N. Protein quality control in the endoplasmic reticulum. APMIS 2003;Suppl:86-91.
64. Kobayashi T, Tanaka K, Inoue K, Kakizuka A. Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells. J Biol Chem 2002;277:47358-65.
65. Nagahama M, Suzuki M, Hamada Y, et al. SVIP is a novel VCP/p97-interacting protein whose expression causes cell vacuolation. Mol Biol Cell 2003;14:262-73.
66. Wang Q, Song C, Li CC. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. J Struct Biol 2004;146:44-57.
67. Meyer HH. Golgi reassembly after mitosis: the AAA family meets the ubiquitin family. Biochim Biophys Acta 2005;1744:108-19.
68. Fratta P, Engel WK, McFerrin J, Davies KJ, Lin SW, Askanas V. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-β precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 2005;167:517-26.
69. Wojcik C, Yano M, DeMartino GN. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/ proteasome-dependent proteolysis. J Cell Sci 2004;117:281-92.
70. Lippincott-Schwartz J, Snapp E, Kenworthy A. Studying protein dynamics in living cells. Nat Rev Mol Cell Biol 2001;2:444-56.
71. Wang Y, Satoh A, Warren G, Meyer HH. VCIP135 acts as a deubiquitinating enzyme during p97-47-mediated reassembly of mitotic Golgi fragments. J Cell Biol 2004;164:973-8.
72. Uchiyama K, Kondo H. p97/p47-mediated biogenesis of Golgi and ER. J Biochem (Tokyo) 2005;137:115-9.
73. Kano F, Kondo H, Yamamoto A, et al. NSF/SNAPs and p97/p47/VCIP135 are sequentially required for cell cycle-dependent reformation of the ER network. Genes Cells 2005;10:989-99.
74. Woodman PG. p97, a protein coping with multiple identities. J Cell Sci 2003;116:4283-90.
75. Chavany C, Mimnaugh E, Miller P, et al. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 1996;271:4974-7.
76. Xu W, Mimnaugh EG, Kim JS, Trepel JB, Neckers LM. Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. Cell Stress Chaperones 2002;7:91-6.
77. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003;284:78-88.
78. Uchiyama K, Jokitalo E, Kano F, et al. VCIP135, a novel essential factor for p97/p47-mediated membrane fusion, is required for Golgi and ER assembly in vivo. J Cell Biol 2002;159:855-66.
79. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003;100:9946-51.
80. Prince T, Shao J, Matts RL, Hartson SD. Evidence for chaperone heterocomplexes containing both Hsp90 and VCP. Biochem Biophys Res Commun 2005;331:1331-7.
81. Nomura M, Nomura N, Newcomb EW, Lukyanov Y, Tamasdan C, Zagzag D. Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells. J Cell Physiol 2004;201:374-84.
82. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A 1997;94:855-60.
83. Cao K, Nakajima R, Meyer HH, Zheng Y. The AAA-ATPase Cdc48/p97 regulates spindle disassembly at the end of mitosis. Cell 2003;115:355-67.
84. Nichols BJ, Pelham HR. SNAREs and membrane fusion in the Golgi apparatus. Biochim Biophys Acta 1998;1404:9-31.
85. 1 transition. Cell Cycle 2004;3:422-4.
86. Mayr PS, Allan VJ, Woodman PG. Phosphorylation of p97(VCP) and p47 in vitro by p34cdc2 kinase. Eur J Cell Biol 1999;78:224-32.
87. Asai T, Tomita Y, Nakatsuka S, et al. VCP (p97) regulates NFκB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002;93:296-304.
88. Partridge JJ, Lopreiato JO, Jr., Latterich M, Indig FE. DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP. Mol Biol Cell 2003;14:4221-9.
89. 784 in response to DNA damage. Cancer Res 2005;65:7533-40.
90. Yamamoto S, Tomita Y, Nakamori S, et al. Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol 2003;21:447-52.
91. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res 2004;10:651-7.
92. Yamamoto S, Tomita Y, Hoshida Y, et al. Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol 2004;11:697-704.
93. Tsujimoto Y, Tomita Y, Hoshida Y, et al. Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res 2004;10:3007-12.
94. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92:1564-72.
95. Smith PK, Krohn RI, Hermanson GT, et al. BCA protein assay. Anal Biochem 1985;150:76-85.
96. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 1970;227:680-5.
97. Swerdlow PS, Finley D, Varshavsky A. Enhancement of immunoblot sensitivity by heating of hydrated filters. Anal Biochem 1986;156:147-53.
98. Mimnaugh EG, Neckers LM. Immunoblotting methods for the study of protein ubiquitination. Methods Mol Biol 2002;194:179-203.
99. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter disposition, a novel method of signal amplification. J Immunol Methods 1989;125:279-85.